Genmab kept at neutral by Merrill

Merrill Lynch analyst Erica Whittaker kept Genmab at a neutral rating following release of the company's financial results for the first-half of the year. Genmab reported revenues of Dkr74 million, compared to the analyst's forecast of Dkr75 million. The company's loss per share of Dkr5.0 was slightly better than the analyst's estimate of Dkr5.8. According to the analyst, Genmab has one of the most attractive product pipelines in European biotech. A deal on HuMax-EGFr could be signed in late 2006 at the earliest, but is expected in early 2007. Shares of the Copenhagen, Denmark, biotechnology company were up Dkr1.00, or 0.50%, at Dkr200.00. (Copenhagen: GEN DC)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.